Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) Inc announced that a new trial site has been added to its clinical study of B-Series optical coherence tomography (OCT) combined with its proprietary ImgAssist AI software.
The latest location is the Baptist MD Anderson Cancer Center in Jacksonville, Florida under the direction of Laila Samiian.
"We are excited to become the newest active site with three investigators anticipated to participate in this clinical study to assess if the Perimeter B-Series with artificial intelligence demonstrates an improvement over the current standard of care,” Samiian said in a statement.
“Combining optical coherence tomography with deep learning algorithms could assist us, as surgeons, to better identify regions of interest supporting 'real-time' decisions on margin status in the OR – potentially setting a new standard for specimen imaging technology during breast conservation surgery."
Patient enrollment is currently ongoing in the roughly 330-person trial. The study is expected to be completed by the end of the year.
"Our ongoing pivotal clinical trial evaluating our breakthrough-device-designated Perimeter B-Series OCT technology with proprietary, next-gen 'ImgAssist' artificial intelligence continues to advance,” Perimeter CEO Jeremy Sobotta said.
“All initially planned sites have been activated, and we recently received FDA approval to expand the number of institutions to further support patient enrollment. We are excited to initiate Baptist MD Anderson Cancer Center with the goal of further accelerating study completion."
Based in Toronto and Dallas, Perimeter is a medical technology company focusing on ultra-high-resolution, real-time, advanced imaging tools for cancer surgery.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel